Bioregenx, Inc. (OTC: BRGX)

Bioregenx, Inc. operates in the health and wellness industry, focusing on innovative technologies and products aimed at improving microvascular health and remote health monitoring. The company has a diverse portfolio, including dietary supplements, medical devices, and artificial intelligence-driven health solutions. Bioregenx generates revenue through the sale of its proprietary products and services, catering to a broad customer base that includes healthcare practitioners, academic researchers, and consumers.

The company's primary products include the Endocalyx Pro dietary supplement, the GlycoCheck software and medical device, and the DocSun AI Engine, which integrates advanced technologies for remote health monitoring. Bioregenx also offers a range of supplements under the MyBodyRx brand and is developing health and wellness apps such as TruScan.Ai and VitalWellness. These products and services are marketed to healthcare professionals, wellness practitioners, and direct-to-consumer channels.

• DocSun BioMedical Holdings, Inc.: This subsidiary focuses on the DocSun AI Engine, which combines ballistocardiography, photoplethysmography, and optical coherence tomography to provide non-invasive health monitoring. The technology is used in various sectors, including healthcare, transportation, and cybersecurity. DocSun has entered into agreements with large software technology companies to provide technical services and license its technology. The subsidiary is also developing the TruScan.Ai mobile app, which will integrate DocSun's AI Engine to offer comprehensive health monitoring.

• Microvascular Health Solutions, LLC (MVHS): MVHS specializes in research, product development, sales, and education, with a focus on microvascular health. The subsidiary produces the patented Endocalyx Pro dietary supplement and the GlycoCheck software and medical device. MVHS is involved in multiple double-blind placebo studies to explore the impact of Endocalyx Pro on various health conditions. The company derives revenue from the sale of GlycoCheck systems to academic research hospitals, private medical practices, pharmacies, dentists, and wellness practitioners. Additionally, revenue is generated from the sale of Endocalyx Pro to medical wholesalers and resellers.

• NuLife Sciences, Inc.: NuLife functions as a marketing and distribution enterprise, aiming to redefine health and longevity through advanced technologies. The subsidiary markets the MyBodyRx branded supplement line, including Endocalyx Pro, and other health and wellness devices. NuLife is developing the TruScan.Ai mobile app in collaboration with DocSun and the VitalWellness app, which will merge its DNA and epigenetics platform with DocSun technology. The subsidiary generates revenue from the sale of goods and services to doctors, healthcare practitioners, patients, consumers, and wholesale distributors.

• Findit Ai Connect, Inc.: This subsidiary operates Findit.com and Classworx.com, which function as social media content management platforms. Findit.com includes an interactive search engine that allows members to submit URLs for indexing. The company is working on adding an AI component to automate the distribution of member posts across various social media platforms. Findit Ai Connect intends to monetize its websites and platforms through marketing efforts, online content marketing campaigns, and the sale of products and services.

Bioregenx operates in a highly competitive industry, facing challenges from well-established domestic and international market participants. Key competitors include large technology and digital marketing companies such as Alphabet Inc. (Google), Microsoft Corporation, Meta Platforms (Facebook, Instagram), X Corp. (formerly Twitter), and Zillow. These competitors offer a variety of internet-based services, digital marketing platforms, and online advertising tools that overlap with Bioregenx's offerings. The company's competitive advantages include synergistic product formulations, competitive pricing strategies, and advanced operational systems designed to streamline manufacturing and optimize supply chain management. Bioregenx's proprietary AI technology and strategic partnerships with healthcare providers also contribute to its competitive positioning in the telehealth market.

The company's customer base is diverse, including healthcare practitioners, academic researchers, wellness practitioners, and consumers. Bioregenx serves a global market, with a significant portion of its revenue generated from customers in the United States. The company's products and services cater to various sectors, including healthcare, transportation, insurance, and cybersecurity. Bioregenx's focus on preventive healthcare and innovative technologies positions it to capitalize on the growing demand for remote health monitoring and personalized wellness solutions.